It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Leprosy household contacts are generally more prone to develop the disease compared to the general population. Previous studies have demonstrated that genes related to the alternative activation (M2) profile in macrophages are associated with the increased bacillary load in multibacillary leprosy patients (MB), and that contacts of MB patients have a higher risk of contracting the disease. In addition, positive serological responses to PGL-1 or LID-1 are associated with a higher risk of disease. We performed a 5-year follow-up of contacts of leprosy patients and evaluated the pattern of gene and protein expression in cells from contacts that developed leprosy during this period. Leprosy household contacts had decreased soluble CD163 and heme oxygenase 1 (HO-1) serum levels when compared with healthy donors and leprosy patients. In contrast, arginase 1 activities were higher in contacts when compared with both healthy donors and leprosy patients. Of the contacts, 33 developed leprosy during the follow-up. Gene expression analysis revealed reduced ARG1 expression in these contacts when compared with contacts that did not develop disease. Arginase activity was a good predictive marker of protection in contacts (sensitivity: 90.0%, specificity: 96.77%) and the association with serology for anti-PGL-1 and anti-LID-1 increased the sensitivity to 100%. Altogether, the data presented here demonstrate a positive role of arginase against leprosy and suggest that the evaluation of arginase activity should be incorporated into leprosy control programs in order to aid in the decision of which contacts should receive chemoprophylaxis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Oswaldo Cruz Foundation, Leprosy Laboratory, Oswaldo Cruz Institute, Rio de Janeiro, Brazil (GRID:grid.418068.3) (ISNI:0000 0001 0723 0931); Federal University of Rio de Janeiro, Inflammation and Immunity Laboratory, Rio de Janeiro, Brazil (GRID:grid.8536.8) (ISNI:0000 0001 2294 473X)
2 Oswaldo Cruz Foundation, Leprosy Laboratory, Oswaldo Cruz Institute, Rio de Janeiro, Brazil (GRID:grid.418068.3) (ISNI:0000 0001 0723 0931)
3 Oswaldo Cruz Foundation, Immunopharmacology Laboratory, Oswaldo Cruz Institute, Rio de Janeiro, Brazil (GRID:grid.418068.3) (ISNI:0000 0001 0723 0931)
4 Federal University of Bahia, Immunology Service, Professor Edgar Santos University Hospital, Salvador, Brazil (GRID:grid.8399.b) (ISNI:0000 0004 0372 8259); Oswaldo Cruz Foundation, Inflammation and Biomarkers Laboratory, Gonçalo Moniz Institute, Salvador, Brazil (GRID:grid.418068.3) (ISNI:0000 0001 0723 0931)
5 Oswaldo Cruz Foundation, Inflammation and Biomarkers Laboratory, Gonçalo Moniz Institute, Salvador, Brazil (GRID:grid.418068.3) (ISNI:0000 0001 0723 0931)
6 Federal University of Rio de Janeiro, Inflammation and Immunity Laboratory, Rio de Janeiro, Brazil (GRID:grid.8536.8) (ISNI:0000 0001 2294 473X)
7 Oswaldo Cruz Foundation, Clinical Research Laboratory in Chagas Disease, National Institute of Infectology Evandro Chagas, Rio de Janeiro, Brazil (GRID:grid.418068.3) (ISNI:0000 0001 0723 0931)